Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Dick’s Sporting Goods Analysts Increase Their Forecasts After Upbeat Results

Dick's Sporting Goods Inc (NYSE: DKS) reported better-than-expected third-quarter financial results on Tuesday.
byLisa Levin
November 22, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Dick’s Sporting Goods Inc (NYSE:DKS) reported better-than-expected third-quarter financial results on Tuesday.

Dick’s Sporting Goods reported third-quarter FY23 sales growth of 2.8% year-on-year to $3.042 billion, beating the analyst consensus estimate of $2.940 billion. Adjusted EPS of $2.85 beat the analyst consensus of $2.45, according to data from Benzinga Pro.

Dick’s Sporting Goods raised full-year adjusted EPS outlook to $12.00-$12.60, up from $11.50-$12.30 previously.

Dick’s Sporting shares rose 0.1% to trade at $121.66 on Wednesday.

These analysts made changes to their price targets on Dick’s Sporting following earnings announcement.

  • Telsey Advisory Group raised the price target on Dick’s Sporting from $140 to $145. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating.
  • Morgan Stanley boosted the price target on Dick’s Sporting from $145 to $150. Morgan Stanley analyst Simeon Gutman maintained an Overweight rating.
  • Wedbush increased the price target on Dick’s Sporting from $115 to $130. Wedbush analyst Seth Basham maintained a Neutral rating.

 

Also Check This Out: Jim Cramer Calls Major Automaker Stock A ‘Wait And See Situation’ — ‘I Want To See The Quarter’

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Actinium Highlights Administration Of Targeted Radiotherapy Iomab-B Across Various BMT Centers With Ease And Without Increasing Radiation Exposure Risks To Treating Nursing Staff In The Pivotal Phase 3 SIERRA Trial At The 48th Annual ONS Congress

By Happy Mohamed
April 28, 8:13 AM
-  24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or refractory acute

ATNM

Read More

US Stocks Start New Trading Week On Negative Note Amid Lack Of Clarity On Rate Outlook — China Stocks Rip Higher; Apple, Tesla In Spotlight

By Shanthi Rexaline
December 5, 7:01 AM
The index futures are pointing to a moderately lower opening by Wall Street stocks on Monday after the averages closed Friday’s session narrowly mixed in reaction to the November non-farm payrolls report.

AAPL